News Briefing channel feed – Endpoints News

News Briefing channel feed

Biohaven recruits a Kardashian to help sell migraine drug; GSK licenses lentiviral tech to Orchard

5 years ago

J&J nabs new OK for IL-23 drug Tremfya; Merck KGaA spinout ups Series A tally to €20.1M

5 years ago

Celsion takes a nosedive as board recommends trial halt; Three biotech IPOs set terms above $90M

5 years ago

AstraZeneca signs computational drug discovery collaboration; J&J-partnered Fate cleared for the clinic

5 years ago

Biopharma companies pledge $1B to fund antibiotics R&D as field shrivels; Four biotechs hunt $797M+

5 years ago

Zai Lab inks China deal with Turning Point with $25M upfront; Xencor, Atreca team up on bispecifics

5 years ago

Boehringer Ingelheim ties the knot with Numab on new antibodies; Cabaletta inks pact with Artisan

5 years ago

Poseida tees $150M IPO; Gilead sends HBV program back to Precision; New HIV data from Merck, Gilead

5 years ago

Biogen bags an AAV gene therapy program from Massachusetts Eye and Ear; Biotechs raised $1B-plus in latest round of follow-ons

5 years ago

Rubius marks milestone in PhI/II as CFO departs; Owkin closes $70M Series A; The Carlyle Group bets on Indian CDMO

5 years ago

EMA removes negative note on label of PTC's Duchenne drug; GSK, Akebia win Japan OK for oral anemia drugs

5 years ago

J&J scuttles PhIII lupus program on failed data analysis; Novartis pays $345M to resolve bribery charges

5 years ago

CRISPR Therapeutics blueprints cell therapy manufacturing site; Regeneron fights back against kickback claims

5 years ago

Biohaven reports another trial failure for troriluzole; Cyclica raises C$23M for AI driven discovery platform

5 years ago

Boehringer Ingelheim to cash out Hikma stake; Breast cancer biotech sets terms for IPO

5 years ago

Looking at a groundbreaking advance, Myovant gets a priority review at FDA; Agenus, G1 forge new China deals

5 years ago

Ultragenyx’s ultra-expensive ultra-rare disease drug earns second nod; Another round of promising NASH data

5 years ago

AbbVie’s Rinvoq passes PhIII AD test; Dicerna races Alnylam; New Sarepta gene & cell collab

5 years ago

Avidity tops up IPO at $298M; Bristol Myers keeps a Celgene discovery pact alive

5 years ago

Protein degradation pioneer C4 Therapeutics nabs $170M; Barcelona startup has €30M to go after cancer metastases

5 years ago

On a hiring spree, Moderna recruits another Amgen vet for the executive committee; Repare, Forma set terms for IPO

5 years ago

Sanofi and Regeneron outline Dupixent plans; Industry lobbying brings £30 million for UK's Biomedical Catalyst

5 years ago

Two preclinical biotechs riding the IPO wave this week look to raise $466M-plus; Blackstone's Galakatos backs Reata to the tune of $350M

5 years ago

Rare disease startup NFlection scores $20M in Series A haul; Gilead partner Galapagos signs pact with Oxford biotech

5 years ago

First page Previous page 39 40 414243 44 45 Next page Last page